← All trials
NCT07010822
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 8, 2025
- Primary completion
- Sep 21, 2026
- Completion date
- Sep 21, 2026
- First posted
- Jun 8, 2025
- Last posted
- Jul 24, 2025
- Enrollment
- 740
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fidec CorporationLead sponsor
- Bill and Melinda Gates FoundationCollaborator
- International Center for Diarrheal Disease ResearchOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.